Capricor begins phase II trial of COVID-19 cell therapy
Capricor Therapeutics has begun a phase II trial of its CAP-1002 cell therapy for patients with severe COVID-19 disease.
Minaris to manufacture Mustang Bio's lentiviral gene therapy in Europe
Minaris Regenerative Medicine has signed an agreement with Mustang Bio to enable technology transfer and good manufacturing practice clinical manufacturing of Mustang's MB-107 lentiviral gene therapy program for the treatment of X-linked severe combined immunodeficiency.
ImmunityBio touts preclinical data on NK cell therapy boosting product
ImmunityBio has released preclinical data demonstrating that its lead cytokine infusion protein, Anktiva, an interleukin-15 "superagonist," improves interferon-gamma production and killing of tumor cells in vitro and in vivo by CD34+ progenitor-derived natural killer (NK) cells.
Regulatory Roundup: Gene therapies, bispecific antibodies lead new approvals
Welcome to Regulatory Roundup, a new Science Advisory Board feature that tracks recent regulatory activities in the life sciences industry. Recent approvals over the past week have included an orphan drug designation for a new gene therapy, as well as approvals for a quadrivalent flu vaccine and a hepatitis B vaccine.
CRISPR phage offers precision medicine tool to fight bacterial infections
In an attempt to combat bacterial infections, Locus Biosciences is developing bacteriophage therapies that deliver CRISPR-Cas3 machinery directly to specific, targeted pathogens to obliterate them. Locus CEO Paul Garofolo discusses the company's technology and recent updates with The  Discuss
Immunomic, Colmmune partner on cancer immunotherapy
Immunomic Therapeutics and CoImmune Therapeutics have entered into a license agreement for Immunomic to use CoImmune's proprietary dendritic cell process for certain Immunomic cell therapy vaccine programs.
Lilly, Precision BioSciences collaborate on genome editing
Eli Lilly and Precision BioSciences have entered a research collaboration and exclusive licensing agreement to utilize Precision's proprietary Arcus genome editing platform for potential in vivo therapies for genetic disorders.
Prevail Therapeutics granted gene therapy patent
The U.S. Patent and Trademark Office has issued a composition of matter patent (No. 10,837,028) to Prevail Therapeutics for its adeno-associated viral vector used in PR001, an experimental gene therapy program for the treatment of Parkinson's disease with mutations in the BGA1 gene and neuropathic Gaucher disease.
Cue Biopharma, Merck expand Immuno-STAT collaboration
Cue Biopharma has extended the terms of its research collaboration and license agreement with Merck toward developing new clinical candidates for the treatment of type 1 diabetes and an additional undisclosed autoimmune disease. The research will focus on in vivo Immuno-selective targeting and alteration of T cell (STAT) biologics that are designed for targeted modulation of disease-associated T cells in immune-oncology and autoimmune diseases.
AbCellera acquires Trianni for $90M
Artificial intelligence-powered biotech and drug discovery platform AbCellera has purchased Trianni for $90 million. The deal boosts AbCellera's ability to create large human antibody databases for drug discovery.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter